Toronto Innovation Acceleration Partners
Deals on record
2
Common Fundraising Type
Seed
Radiant Bio
Multabody™ platform • Oncology
Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.
HDAX Therapeutics
Preclinical development • Pipeline advancement
HDAX Therapeutics is developing next-generation HDAC6 inhibitors to treat neurological and cardiometabolic diseases.